Bluebird bio Inc [BLUE] stock is trading at $4.97, saw in change for the day. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BLUE shares have gain 42.00% over the last week, with a monthly amount glided 19.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bluebird bio Inc [NASDAQ: BLUE] stock has seen the most recent analyst activity on February 24, 2025, when JP Morgan upgraded its rating to a Neutral. Previously, JP Morgan downgraded its rating to Underweight on November 15, 2024. On November 15, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $0.50 on the stock. JP Morgan downgraded its rating to a Neutral. HSBC Securities downgraded its rating to a Reduce. Morgan Stanley upgraded its rating to Equal-Weight for this stock on December 08, 2023, and upped its price target to $7. In a note dated October 17, 2023, Cantor Fitzgerald initiated an Neutral rating.
Bluebird bio Inc [BLUE] stock has fluctuated between $3.20 and $28.60 over the past year. Currently, Wall Street analysts expect the stock to reach $13.69 within the next 12 months. Bluebird bio Inc [NASDAQ: BLUE] shares were valued at $4.97 at the most recent close of the market. An investor can expect a potential return of 175.45% based on the average BLUE price forecast.
Analyzing the BLUE fundamentals
Bluebird bio Inc [NASDAQ:BLUE] reported sales of 103.95M for the trailing twelve months, which represents a growth of 108.43%. Gross Profit Margin for this corporation currently stands at 0.27% with Operating Profit Margin at -2.08%, Pretax Profit Margin comes in at -1.92%, and Net Profit Margin reading is -1.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is 18.95 and Total Capital is 11.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.96 points at the first support level, and at 4.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.98, and for the 2nd resistance point, it is at 5.00.
Ratios To Look Out For
For context, Bluebird bio Inc’s Current Ratio is 0.55. Further, the Quick Ratio stands at 0.29, while the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 0.47.
Transactions by insiders
Recent insider trading involved Colvin Richard A, Chief Medical Officer, that happened on Mar 03 ’25 when 584.0 shares were sold., Klima Thomas J completed a deal on Mar 03 ’25 to sell 500.0 shares. Meanwhile, President and CEO Obenshain Andrew sold 921.0 shares on Mar 03 ’25.
